5 Best Value ETFs To Invest In

3. SPDR S&P 600 Small Cap Value ETF (NYSE:SLY)

The SPDR S&P 600 Small Cap Value ETF (NYSE:SLY) seeks to provide investment results that correspond generally to the total return performance of the S&P SmallCap 600 Index, which includes U.S. companies typically between $600 million and $2.4 billion in market value. The fund holds 475 stocks with an average P/E of about 15, and invests heavily in the financials and industrial sectors, which make up 16.98% and 15.3% of the fund’s portfolio, respectively.

One of the largest holdings of the ETF is Lantheus Holdings, Inc. (NASDAQ:LNTH), a holding company that provides innovative diagnostics, targeted therapeutics and artificial intelligence (AI) solutions. Earlier this May, B. Riley analyst Justin Walsh initiated coverage of Lantheus Holdings, Inc. (NASDAQ:LNTH) with a Buy rating and $91 price target. Lantheus, which he calls the “leading diagnostic imaging and nuclear medicine company,” is well positioned in the rapidly growing radiopharmaceutical space and is expected to nearly double revenues in FY22 given the expected strong launch of prostate cancer imaging agent Pylarify, Walsh tells investors.

According to Insider Monkey’s database, Lantheus Holdings, Inc. (NASDAQ:LNTH) was in 35 hedge fund portfolios at the end of the first quarter of 2022, compared to 15 funds in the previous quarter. Israel Englander’s Millennium Management is the leading shareholder of the company, with a stake worth approximately $92.83 million.

Here is what Clearbridge Investments Small Cap Strategy has to say about Lantheus Holdings, Inc. (NASDAQ:LNTH) in its Q1 2022 investor letter:

“While companies with immature business models and no profits exist throughout the market, there are certain sectors where they congregate more easily, such as health care. As access to cheap capital recedes, however, many of these specialty drug and biotech companies will likely find it challenging to dismiss long periods of unprofitability. While we have had limited exposure in the sector, our focus on finding high-quality companies at attractive valuations has yielded positive results. For example, Lantheus Holdings (NASDAQ:LNTH) is a global leader in medical diagnostic imaging whose core business suffered during the COVID-19 pandemic due to a dramatic decline in hospital visits. As hospitals return to a level of normalcy, Lantheus’s core business has rebounded. Additionally, in late 2021 the company received approval for its new radio-pharmacological drug, Pylarify, for the treatment of prostate cancer, and initial sales have been well ahead of expectations. We believe it has a strong future in oncology diagnosis and treatment. As a result, Lantheus was our strongest individual performer for the first quarter.”